Pancryos strikes deal with Brigham and Women’s Hospital on type 1 diabetes drug
The Copenhagen-based firm has entered a global license agreement with Brigham and Women’s Hospital regarding an encapsulation device for the delivery of a stem-cell derived treatment for type 1 diabetes.
by christopher due karlsson, translated by daniel pedersen
Pancryos, which is based out of Copenhagen, Denmark, is working on a stem-cell based treatment for type 1 diabetes dubbed Paninsula, and has now signed an exclusive license deal with the US-based Brigham and Women’s Hospital (BWH), the firm reports in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Dexcom is in talks to acquire device firm Insulet
For subscribers
Novo Nordisk regains Novorapid supply capacity
For subscribers
FDA approves Eli Lilly diabetes drug
For subscribers
